Liu Danni, Chen Jiayi, Chen Hongmei, Hu Wenxue, Lin Jinxin
Department of Nephrology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangdong Provincial Geriatrics Institute, Southern Medical University, Guangzhou, China.
Department of Endocrinology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangdong Provincial Geriatrics Institute, Southern Medical University, Guangzhou, China.
Case Rep Endocrinol. 2025 Sep 4;2025:4553039. doi: 10.1155/crie/4553039. eCollection 2025.
Fibrous dysplasia (FD) is a rare congenital bone disease. Denosumab, a monoclonal antibody targeting nuclear factor kappa-B ligand (RANKL), suppresses osteoclast activity and exhibits therapeutic potential for FD. We present the case of an adult female patient diagnosed with FD who had undergone 7 treatment cycles of denosumab (120 mg/dose, sc.) with a cumulative dose of 840 mg. After discontinuing denosumab for 7 months, the patient experienced a crisis of rebound hypercalcemia. Although, rare reports of hypercalcemia induced by discontinuation of denosumab are primarily seen in adolescents. By reporting this case, we aim to alert clinicians to the risk of rebound hypercalcemia in adult patients with FD undergoing denosumab treatment.
骨纤维发育不良（FD）是一种罕见的先天性骨病。地诺单抗是一种靶向核因子κB配体（RANKL）的单克隆抗体，可抑制破骨细胞活性，并显示出对FD的治疗潜力。我们报告了一例成年女性患者，该患者被诊断为FD，接受了7个周期的地诺单抗治疗（120mg/剂量，皮下注射），累积剂量为840mg。在停用7个月后，患者经历了反弹性高钙血症危机。虽然，停用后诱导高钙血症的罕见报告主要见于青少年。通过报告这个病例，我们旨在提醒临床医生，接受地诺单抗治疗的成年FD患者存在反弹性高钙血症的风险。
